Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies. (Q53623806)

16 May 2018

title

Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies. (English)

1 reference

16 May 2018

1 reference

1 reference

4

Branimir I Sikic

1 reference

16 May 2018

author name string

Cheryl D Cho

series ordinal

1

1 reference

16 May 2018

George A Fisher

series ordinal

2

1 reference

16 May 2018

Joanne Halsey

series ordinal

3

1 reference

16 May 2018

publication date

1 March 2006

1 reference

16 May 2018

Investigational New Drugs

published in

1 reference

16 May 2018

volume

24

1 reference

16 May 2018

issue

2

1 reference

16 May 2018

page(s)

117-123

1 reference

16 May 2018

Epidermal growth factor receptor expression and measurement in solid tumors

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-006-2032-7

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase

21 January 2018

1 reference

12 December 2020

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

12 December 2020

Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor

1 reference

12 December 2020

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

12 December 2020

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

12 December 2020

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

12 December 2020

Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer

1 reference

12 December 2020

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

12 December 2020

Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma

1 reference

12 December 2020

Epidermal growth factor receptor-targeted therapy in colorectal cancer

1 reference

12 December 2020

Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.

1 reference

12 December 2020

Early-stage lung cancer findings end a debate, put focus on next steps

1 reference

12 December 2020

ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression

1 reference

12 December 2020

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

12 December 2020

Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil

1 reference

12 December 2020

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

12 December 2020

EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs.

1 reference

12 December 2020

Development of ZD1839 in colorectal cancer

1 reference

12 December 2020

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

1 reference

12 December 2020

10.1007/S10637-006-2032-7

Identifiers

DOI

1 reference

16 May 2018

1 reference

16 May 2018